This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell non-Hodgkin’s lymphoma (NHL). The main outcomes to be measured will be the complete response rate and the occurrence of side effects after treatment. This study is recruiting in Miami, Florida, New York City, New York, and Duarte, California, the USA.
The details
Mosunetuzumab is a new targeted therapy. This treatment helps T-cells (an important cell type in the body’s immune system) attack cancer cells. This leads to cancer cell death. Polatuzumab vedotin is a new monoclonal antibody. This type of treatment binds to cancer cells, leading to cancer cell death.
This trial is examining the safety and effectiveness of mosunetuzumab plus polatuzumab vedotin for B-cell NHL. One of the main outcomes to be measured will be the complete response rate (how many patients have the disappearance of all signs of cancer). The occurrence of side effects after treatment will also be measured.
Who are they looking for?
This study is recruiting 276 patients with diffuse large B-cell lymphoma or follicular lymphoma that have been previously treated. They should have adequate liver, kidney and blood cell count tests.
Patients should not have had prior treatment with mosunetuzumab or polatuzumab vedotin. Patients should not have had a prior allogeneic stem cell transplant or solid organ transplant. Patients should not have a history of autoimmune disease or nerve disease.
How will it work
This trial involves three main groups of patients. The first group will receive mosunetuzumab plus polatuzumab vedotin. The best dose of study treatment will be determined in this group. The second and third groups will receive other standard treatments for NHL that will be compared to the study treatment.
This trial will also involve four additional groups of patients. These groups will receive mosunetuzumab and polatuzumab vedotin together or as monotherapies (single agent therapy).
One of the main outcomes to be measured will be the complete response rate at 6 months after treatment. The occurrence of side effects at 3 months after treatment will also be measured.
